SQZ Biotechnologies (OTCMKTS:SQZB – Get Free Report) is anticipated to announce its resultson Thursday, November 12th. Analysts expect SQZ Biotechnologies to announce earnings of ($0.5825) per share and revenue of $4.66 million for the quarter.
SQZ Biotechnologies Price Performance
Shares of OTCMKTS:SQZB opened at $0.02 on Thursday. SQZ Biotechnologies has a twelve month low of $0.01 and a twelve month high of $0.05. The stock’s 50 day moving average is $0.02 and its 200-day moving average is $0.02.
About SQZ Biotechnologies
SQZ Biotechnologies Co was a biotechnology company that developed cell therapies using its proprietary Cell Squeeze technology. The platform was designed to deliver biological materials, including proteins, nucleic acids and other therapeutic payloads, directly into cells while preserving cell viability and function.
The company focused primarily on oncology and immunology applications. Its research programs included engineered immune-cell therapies intended to stimulate anti-tumor responses, including programs involving antigen-presenting cells and peripheral blood mononuclear cells.
See Also
- Five stocks we like better than SQZ Biotechnologies
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for SQZ Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SQZ Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
